← Back to Search

Cancer Vaccine

Vaccine Response with Chemical Exposure

Phase 4
Waitlist Available
Led By Robert Laumbach, MD
Research Sponsored by Rutgers, The State University of New Jersey
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Weigh at least 110 pounds
Be older than 18 years old
Must not have
Currently taking immune suppressants
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 30 days
Awards & highlights
No Placebo-Only Group
Pivotal Trial
Drug Has Already Been Approved

Summary

"This trial aims to see how exposure to a certain chemical called PFNA affects the immune response to the tetanus and diphtheria vaccine. The study will involve people from a community that has been

Who is the study for?
This trial is for adults who have been exposed to PFNA through contaminated drinking water. It's designed to see if this exposure affects how their immune system responds to the Td vaccine. Participants will need to visit the study office seven times over a month and provide blood and saliva samples.
What is being tested?
The clinical trial is testing whether prior exposure to PFNA impacts the effectiveness of the TENIVAC (Td) booster shot, by measuring antibody levels in participants' blood and saliva after vaccination.
What are the potential side effects?
While not explicitly listed, side effects may include those commonly associated with vaccines such as soreness at injection site, mild fever, fatigue, headache or allergic reactions.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I weigh at least 110 pounds.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I am currently on immune suppressants.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~30 days
This trial's timeline: 3 weeks for screening, Varies for treatment, and 30 days for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Change in Tetanus-diptheria specific IgG

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Pivotal Trial
The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
Drug Has Already Been Approved
The FDA has already approved this drug, and is just seeking more data.

Trial Design

1Treatment groups
Experimental Treatment
Group I: All participantsExperimental Treatment1 Intervention
All participants will be vaccinated during their first study visit using TENIVAC (Tetanus and Diphtheria Toxoids Adsorbed).TENIVAC will be administered intramuscularly as recommended in the subject's deltoid muscle at a dose of 0.5 mL.

Find a Location

Who is running the clinical trial?

Rutgers, The State University of New JerseyLead Sponsor
444 Previous Clinical Trials
65,946 Total Patients Enrolled
Robert Laumbach, MDPrincipal InvestigatorRutgers, The State University of New Jersey
~13 spots leftby Aug 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top